vs
Pacira BioSciences, Inc.（PCRX）とStrategic Education, Inc.（STRA）の財務データ比較。上の社名をクリックして会社を切り替えられます
Strategic Education, Inc.の直近四半期売上が大きい（$305.9M vs $177.4M、Pacira BioSciences, Inc.の約1.7倍）。Strategic Education, Inc.の純利益率が高く（10.7% vs 1.6%、差は9.1%）。Pacira BioSciences, Inc.の前年同期比売上増加率が高い（5.0% vs 0.8%）。過去8四半期でPacira BioSciences, Inc.の売上複合成長率が高い（-0.2% vs -1.0%）
Pacira BioSciences社は非オピオイド系疼痛管理ソリューションの開発・商業化に特化した専門製薬企業で、主に米国の病院や外来手術センターなどの医療機関に術後鎮痛向け製品を提供し、一部海外市場への展開も進めています。
Strategic Education, Inc.（SEI）は教育サービスを事業とする持ち株会社で、旧社名はStrayer Education, Inc.です。営利目的のオンライン大学であるカペラ大学、ストレイヤー大学を傘下に所有するほか、DevMountain、Hackbright Academy、Sophia Learningなどの非学位コースを提供する教育機関も運営しています。
PCRX vs STRA — 直接比較
損益計算書 — Q1 FY2026 vs Q1 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $177.4M | $305.9M |
| 純利益 | $2.9M | $32.8M |
| 粗利率 | — | — |
| 営業利益率 | 3.9% | 13.4% |
| 純利益率 | 1.6% | 10.7% |
| 売上前年比 | 5.0% | 0.8% |
| 純利益前年比 | — | 10.3% |
| EPS（希薄化後） | $0.07 | $1.48 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q1 26 | $177.4M | $305.9M | ||
| Q4 25 | $196.9M | $323.2M | ||
| Q3 25 | $179.5M | $319.9M | ||
| Q2 25 | $181.1M | $321.5M | ||
| Q1 25 | $168.9M | $303.6M | ||
| Q4 24 | $187.3M | $311.5M | ||
| Q3 24 | $168.6M | $306.0M | ||
| Q2 24 | $178.0M | $312.3M |
| Q1 26 | $2.9M | $32.8M | ||
| Q4 25 | — | $37.9M | ||
| Q3 25 | $5.4M | $26.6M | ||
| Q2 25 | $-4.8M | $32.3M | ||
| Q1 25 | $4.8M | $29.7M | ||
| Q4 24 | — | $25.3M | ||
| Q3 24 | $-143.5M | $27.7M | ||
| Q2 24 | $18.9M | $29.9M |
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | — | ||
| Q3 25 | 80.9% | — | ||
| Q2 25 | 77.4% | — | ||
| Q1 25 | 79.7% | — | ||
| Q4 24 | 78.7% | — | ||
| Q3 24 | 76.9% | — | ||
| Q2 24 | 75.1% | — |
| Q1 26 | 3.9% | 13.4% | ||
| Q4 25 | 1.2% | 16.0% | ||
| Q3 25 | 3.5% | 11.6% | ||
| Q2 25 | 4.7% | 14.2% | ||
| Q1 25 | 1.2% | 13.1% | ||
| Q4 24 | 13.2% | 11.6% | ||
| Q3 24 | -82.8% | 11.9% | ||
| Q2 24 | 15.9% | 13.4% |
| Q1 26 | 1.6% | 10.7% | ||
| Q4 25 | — | 11.7% | ||
| Q3 25 | 3.0% | 8.3% | ||
| Q2 25 | -2.7% | 10.1% | ||
| Q1 25 | 2.8% | 9.8% | ||
| Q4 24 | — | 8.1% | ||
| Q3 24 | -85.1% | 9.1% | ||
| Q2 24 | 10.6% | 9.6% |
| Q1 26 | $0.07 | $1.48 | ||
| Q4 25 | $0.05 | $1.65 | ||
| Q3 25 | $0.12 | $1.15 | ||
| Q2 25 | $-0.11 | $1.37 | ||
| Q1 25 | $0.10 | $1.24 | ||
| Q4 24 | $0.38 | $1.05 | ||
| Q3 24 | $-3.11 | $1.15 | ||
| Q2 24 | $0.39 | $1.24 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $144.3M | $150.3M |
| 総負債低いほど良い | — | — |
| 株主資本純資産 | $653.9M | $1.6B |
| 総資産 | $1.2B | $2.1B |
| 負債/資本比率低いほどレバレッジが低い | — | — |
8四半期トレンド — 暦四半期で整列
| Q1 26 | $144.3M | $150.3M | ||
| Q4 25 | $238.4M | $148.1M | ||
| Q3 25 | $246.3M | $172.6M | ||
| Q2 25 | $445.9M | $164.9M | ||
| Q1 25 | $493.6M | $182.6M | ||
| Q4 24 | $484.6M | $184.0M | ||
| Q3 24 | $453.8M | $222.1M | ||
| Q2 24 | $404.2M | $256.2M |
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | — | ||
| Q3 25 | $376.7M | — | ||
| Q2 25 | $580.5M | — | ||
| Q1 25 | $583.4M | — | ||
| Q4 24 | $585.3M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | $653.9M | $1.6B | ||
| Q4 25 | $693.1M | $1.6B | ||
| Q3 25 | $727.2M | $1.7B | ||
| Q2 25 | $757.8M | $1.7B | ||
| Q1 25 | $798.5M | $1.6B | ||
| Q4 24 | $778.3M | $1.7B | ||
| Q3 24 | $749.6M | $1.7B | ||
| Q2 24 | $879.3M | $1.7B |
| Q1 26 | $1.2B | $2.1B | ||
| Q4 25 | $1.3B | $2.0B | ||
| Q3 25 | $1.3B | $2.1B | ||
| Q2 25 | $1.5B | $2.1B | ||
| Q1 25 | $1.6B | $2.1B | ||
| Q4 24 | $1.6B | $2.0B | ||
| Q3 24 | $1.5B | $2.2B | ||
| Q2 24 | $1.6B | $2.2B |
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | — | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | — | $87.4M |
| フリーキャッシュフロー営業CF - 設備投資 | — | $77.3M |
| FCFマージンFCF / 売上 | — | 25.3% |
| 設備投資強度設備投資 / 売上 | — | — |
| キャッシュ転換率営業CF / 純利益 | — | 2.66× |
| 直近12ヶ月FCF直近4四半期 | — | $173.9M |
8四半期トレンド — 暦四半期で整列
| Q1 26 | — | $87.4M | ||
| Q4 25 | $43.7M | $39.2M | ||
| Q3 25 | $60.8M | $60.1M | ||
| Q2 25 | $12.0M | $31.2M | ||
| Q1 25 | $35.5M | $67.7M | ||
| Q4 24 | $33.1M | $15.9M | ||
| Q3 24 | $53.9M | $51.5M | ||
| Q2 24 | $53.2M | $24.3M |
| Q1 26 | — | $77.3M | ||
| Q4 25 | $43.5M | $27.0M | ||
| Q3 25 | $57.0M | $49.3M | ||
| Q2 25 | $9.3M | $20.4M | ||
| Q1 25 | $26.9M | $57.3M | ||
| Q4 24 | $31.0M | $4.7M | ||
| Q3 24 | $49.8M | $42.1M | ||
| Q2 24 | $51.6M | $13.6M |
| Q1 26 | — | 25.3% | ||
| Q4 25 | 22.1% | 8.3% | ||
| Q3 25 | 31.7% | 15.4% | ||
| Q2 25 | 5.1% | 6.3% | ||
| Q1 25 | 15.9% | 18.9% | ||
| Q4 24 | 16.6% | 1.5% | ||
| Q3 24 | 29.6% | 13.8% | ||
| Q2 24 | 29.0% | 4.3% |
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 3.8% | ||
| Q3 25 | 2.2% | 3.4% | ||
| Q2 25 | 1.5% | 3.4% | ||
| Q1 25 | 5.1% | 3.4% | ||
| Q4 24 | 1.1% | 3.6% | ||
| Q3 24 | 2.4% | 3.1% | ||
| Q2 24 | 0.9% | 3.4% |
| Q1 26 | — | 2.66× | ||
| Q4 25 | — | 1.03× | ||
| Q3 25 | 11.20× | 2.26× | ||
| Q2 25 | — | 0.97× | ||
| Q1 25 | 7.37× | 2.27× | ||
| Q4 24 | — | 0.63× | ||
| Q3 24 | — | 1.86× | ||
| Q2 24 | 2.82× | 0.81× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
STRA
| U.S. Higher Education | $212.6M | 69% |
| Australia/New Zealand | $51.8M | 17% |
| Education Technology Services | $41.5M | 14% |
